DE1795438C2 - S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053 - Google Patents

S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053

Info

Publication number
DE1795438C2
DE1795438C2 DE1795438A DE1795438DA DE1795438C2 DE 1795438 C2 DE1795438 C2 DE 1795438C2 DE 1795438 A DE1795438 A DE 1795438A DE 1795438D A DE1795438D A DE 1795438DA DE 1795438 C2 DE1795438 C2 DE 1795438C2
Authority
DE
Germany
Prior art keywords
diamino
preparation
acid methyl
chloropyrazine
elimination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1795438A
Other languages
German (de)
English (en)
Other versions
DE1795438B1 (de
Inventor
Edward Jethro Lansdale R.D. Pa. Cragoejun. (V.St.A.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE1795438B1 publication Critical patent/DE1795438B1/de
Application granted granted Critical
Publication of DE1795438C2 publication Critical patent/DE1795438C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE1795438A 1962-10-30 1963-10-28 S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053 Expired DE1795438C2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (2)

Publication Number Publication Date
DE1795438B1 DE1795438B1 (de) 1973-09-06
DE1795438C2 true DE1795438C2 (de) 1974-04-11

Family

ID=26927694

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1795438A Expired DE1795438C2 (de) 1962-10-30 1963-10-28 S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053
DE19631470053 Pending DE1470053A1 (de) 1962-10-30 1963-10-28 5,6-disubstituierte (3-Aminopyrazinoyl)-guanidinverbindungen und Verfahren zu deren Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19631470053 Pending DE1470053A1 (de) 1962-10-30 1963-10-28 5,6-disubstituierte (3-Aminopyrazinoyl)-guanidinverbindungen und Verfahren zu deren Herstellung

Country Status (13)

Country Link
US (1) US3313813A (cg-RX-API-DMAC10.html)
BE (1) BE639386A (cg-RX-API-DMAC10.html)
BR (1) BR6354164D0 (cg-RX-API-DMAC10.html)
CH (1) CH465617A (cg-RX-API-DMAC10.html)
CY (1) CY440A (cg-RX-API-DMAC10.html)
DE (2) DE1795438C2 (cg-RX-API-DMAC10.html)
DK (4) DK114978B (cg-RX-API-DMAC10.html)
FI (1) FI47102C (cg-RX-API-DMAC10.html)
FR (1) FR1563612A (cg-RX-API-DMAC10.html)
GB (1) GB1066855A (cg-RX-API-DMAC10.html)
MY (1) MY6900026A (cg-RX-API-DMAC10.html)
NL (2) NL142413B (cg-RX-API-DMAC10.html)
SE (1) SE321230B (cg-RX-API-DMAC10.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (cg-RX-API-DMAC10.html) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
WO1992005779A1 (en) * 1990-10-05 1992-04-16 The University Of North Carolina At Chapel Hill Method of administering amiloride
TW213903B (cg-RX-API-DMAC10.html) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
WO1999009998A1 (en) * 1997-08-29 1999-03-04 The University Of North Carolina At Chapel Hill Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
AU2740500A (en) * 1999-01-29 2000-08-18 Beyer, Camille F. Composition and method for treating diabetes
MXPA02000684A (es) 1999-07-19 2003-07-21 Univ North Carolina Conjugados de bloqueadores del canal de sodio y metodos de uso de los mismos.
SK5992003A3 (en) 2000-11-21 2003-11-04 Sankyo Co Medicinal composition comprising an angiotensin II receptor antagonist and one or more diuretics and use thereof
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
KR100668539B1 (ko) 2002-08-19 2007-01-16 화이자 프로덕츠 인크. 과증식성 질환에 대한 조합요법
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7375107B2 (en) * 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007062222A2 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
MX344703B (es) * 2008-02-26 2017-01-03 Parion Sciences Inc Bloqueadores de canal de sodio poliaromaticos.
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
BR112013032771B1 (pt) 2011-06-27 2021-01-12 Parion Sciences, Inc. dipeptídio quimicamente e metabolicamente estável possuindo potente atividade bloqueadora de canais de sódio
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
SG11201407867VA (en) 2012-05-29 2014-12-30 Parion Sciences Inc Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
EP3019492B1 (en) * 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP6927042B2 (ja) * 2016-07-29 2021-08-25 東レ株式会社 グアニジン誘導体及びその医薬用途
MA54261B1 (fr) 2019-01-18 2025-03-28 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299929A (cg-RX-API-DMAC10.html) * 1962-10-30

Also Published As

Publication number Publication date
FI47102B (cg-RX-API-DMAC10.html) 1973-05-31
NL299931A (cg-RX-API-DMAC10.html)
CH465617A (de) 1968-11-30
DK116943B (da) 1970-03-02
DK115403B (da) 1969-10-06
FI47102C (fi) 1973-09-10
BE639386A (cg-RX-API-DMAC10.html)
DK114557B (da) 1969-07-14
FR1563612A (cg-RX-API-DMAC10.html) 1969-04-18
GB1066855A (en) 1967-04-26
MY6900026A (en) 1969-12-31
CY440A (en) 1968-05-18
DE1795438B1 (de) 1973-09-06
SE321230B (cg-RX-API-DMAC10.html) 1970-03-02
DE1470053A1 (de) 1969-06-26
BR6354164D0 (pt) 1973-09-18
DK114978B (da) 1969-08-25
NL142413B (nl) 1974-06-17
US3313813A (en) 1967-04-11

Similar Documents

Publication Publication Date Title
DE1795438C2 (de) S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053
ES282416A1 (es) Procedimiento para la preparación de mezclas de ésteres de sucrosa
FR1264772A (fr) Procédé de préparation d'esters de l'acide acéto-acétique
CH388301A (de) Verfahren zur Herstellung von 2,5-diarylamino-3,6-dihydro-terephthalsäureestern
CH388955A (de) Verfahren zur Herstellung von Dithiophosphonsäureester-amiden
CH394144A (de) Verfahren zur Herstellung von Kanamycin-N,N'-dimethansulfonsäure
DE619017C (de) Herstrellung von Natriumazid
CH423755A (de) Verfahren zur Herstellung von Hexen-(3)-säure-hexen-(3)-yl-ester
GB797147A (en) A process for the manufacture of ice-cream
FR1303225A (fr) Procédé de préparation de l'acide l-glutamique et de l'acide alpha-cétoglutarique
DE868903C (de) Verfahren zur Herstellung von Pyromellithsaeure aus Koks
SU145565A1 (ru) Способ получени дихлорацетамида
DE950466C (de) Verfahren zur Herstellung von Acylaminocarbonsaeureestern
SU367147A1 (ru) Всесоюзная iб>&'&л''''о" '1иа
DE902009C (de) Verfahren zur Herstellung von schwefelhaltigen Verbindungen
GB981123A (en) Improved process for the preparation of nitriles
GB793926A (en) Improvements relating to the preparation of dialkyl esters of terephthalic acid
DE1036856B (de) Verfahren zur Herstellung von Dilactamen
AT208839B (de) Verfahren zur Herstellung von L-(+)-Glutamin
GB1104779A (en) Process for preparing methacrylamide sulphate
SU455969A1 (ru) Способ получени алкиловых эфиров диалкоксифосфинилацетоуксусных кислот
AT142708B (de) Verfahren zur Herstellung therapeutisch verwendbarer Lösungen von Arzneistoffen.
GB907126A (en) Improvements in or relating to terephthalic acid
GB844237A (en) Esters of aromatic dicarboxylic acids
ATE2425T1 (de) Verfahren zur herstellung von n,n'diacetylethylendiamin.

Legal Events

Date Code Title Description
E77 Valid patent as to the heymanns-index 1977